Comparison of myeloid cells in circulation and in the tumor microenvironment of patients with colorectal and breast cancers.
Affiliation
Cancer Research Center, Qatar Biomedical Research Institute, College of Science and Engineering, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar.Issue Date
2017
Metadata
Show full item recordAbstract
We have previously reported levels of myeloid cells in the periphery and in the tumor microenvironment (TME) of patients with primary breast cancer (PBC) and colorectal cancer (CRC). We found that both PBC and CRC patients have significantly higher levels of granulocytic and immature myeloid cells in the TME. Additionally, we reported an expansion of circulating granulocytic myeloid cells in CRC patients, but not in PBC patients. In this report, we compared levels of myeloid cells between these two common cancers and have added data from more cancer patients. We also investigated associations between clinical stage/histological grade of tumors and levels of myeloid cells in cancer patients. We found that although granulocytic myeloid cells were expanded in the TME of both PBC and CRC patients, the levels of these cells were significantly higher in the TME of CRC patients. Moreover, our results indicate that increased levels of circulating granulocytic myeloid cells are associated with poorly differentiated tumors in CRC patients. Taken together, this work suggests that CRC patients may benefit more from the development of therapeutic agents to promote myeloid cell differentiation or inhibition for the reversal of immune suppression.Citation
Comparison of myeloid cells in circulation and in the tumor microenvironment of patients with colorectal and breast cancers. 2017, 2017:7989020 J Immunol ResJournal
Journal of Immunology ResearchDOI
10.1155/2017/7989020PubMed ID
29230424Type
ArticleLanguage
enISSN
2314-7156ae974a485f413a2113503eed53cd6c53
10.1155/2017/7989020
Scopus Count
Collections
Related articles
- Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.
- Authors: Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, Zhu J, Wei H, Zhao K
- Issue date: 2013
- Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma.
- Authors: Sun HL, Zhou X, Xue YF, Wang K, Shen YF, Mao JJ, Guo HF, Miao ZN
- Issue date: 2012 Jul 7
- Prognostic significance of myeloid immune cells and their spatial distribution in the colorectal cancer microenvironment.
- Authors: Väyrynen JP, Haruki K, Väyrynen SA, Lau MC, Dias Costa A, Borowsky J, Zhao M, Ugai T, Kishikawa J, Akimoto N, Zhong R, Shi S, Chang TW, Fujiyoshi K, Arima K, Twombly TS, Da Silva A, Song M, Wu K, Zhang X, Chan AT, Nishihara R, Fuchs CS, Meyerhardt JA, Giannakis M, Ogino S, Nowak JA
- Issue date: 2021 Apr
- Differential gene expression of tumor-infiltrating CD33(+) myeloid cells in advanced- versus early-stage colorectal cancer.
- Authors: Toor SM, Taha RZ, Sasidharan Nair V, Saleh R, Murshed K, Abu Nada M, Elkord E
- Issue date: 2021 Mar
- Myeloid Cells in Circulation and Tumor Microenvironment of Colorectal Cancer Patients with Early and Advanced Disease Stages.
- Authors: Toor SM, Khalaf S, Murshed K, Abu Nada M, Elkord E
- Issue date: 2020